Kyverna Therapeutics, Inc.

Industry / private company


Location: Emeryville, United States (USA) (US) US

Targeting autoimmunity with CD19-CAR T-cell therapy: efficacy and seroconversion in diffuse systemic sclerosis and rheumatoid arthritis (2025) Albach FN, Minopoulou I, Wilhelm A, Biesen R, Kleyer A, Wiebe E, Fleischmann A, et al. Journal article Exploring CAR T-Cell Dynamics: Balancing Potent Cytotoxicity and Controlled Inflammation in CAR T-Cells Derived from Systemic Sclerosis and Myositis Patients (2025) Dingfelder J, Taubmann J, von Heydebrand F, Aigner M, Bergmann C, Knitza J, Park S, et al. Journal article Anti-CD19 CAR T cell therapy induces antibody seroconversion and complete B cell depletion in the bone marrow of a therapy-refractory patient with ANCA-associated vasculitis (2025) Minopoulou I, Wilhelm A, Albach F, Kleyer A, Wiebe E, Schallenberg S, Fleischmann A, et al. Journal article Clinical efficacy and autoantibody seroconversion with CD19-CAR T cell therapy in a patient with rheumatoid arthritis and coexisting myasthenia gravis (2024) Haghikia A, Hegelmaier T, Wolleschak D, Böttcher M, Pappa V, Motte J, Borie D, et al. Journal article Fully Human Anti-CD19 CAR T Cells Derived from Systemic Lupus Erythematosus Patients Exhibit Cytotoxicity with Reduced Inflammatory Cytokine Production (2024) Dingfelder J, Aigner M, Taubmann J, Minopoulou I, Park S, Kaplan CD, Cheng JK, et al. Journal article Anti-CD19 CAR-T cells are effective in severe idiopathic Lambert-Eaton myasthenic syndrome (2024) Wickel J, Schnetzke U, Klink A, Rinke J, Borie D, Dudziak D, Hochhaus A, et al. Journal article Anti-CD19 CAR T cells for refractory myasthenia gravis (2023) Haghikia A, Hegelmaier T, Wolleschak D, Böttcher M, Desel C, Borie D, Motte J, et al. Journal article